CO-WESTERN-UNION
10.6.2021 12:02:10 CEST | Business Wire | Press release
Western Union (NYSE: WU), a global leader in cross-border, cross-currency money movement and payments, continues to make significant headway in expanding its digital platform to provide enhanced services for global customers by enabling national postal networks around the world to offer international digital money transfer services.
Australia Post has become the fifth national postal organization globally to leverage Western Union digital money transfer capabilities, innovating to meet existing and new customers’ needs for global money transfers. Four other national postal institutions already offer Western Union’s digital money transfer services, including France’s La Banque Postal , Italy’s Postepay , Russia’s Russian Post Bank , and the United Kingdom’s Post Office Ltd.
Australia Post has expanded its international services with the launch of Western Union digital money transfers, enabling customers to send money worldwide 24/7, using Western Union’s leading cross-border money transfer capabilities via auspost.com.au . The digital expansion builds on a 17-year relationship with Western Union, which began with the introduction of retail services in 2004.
Western Union’s partnerships with national postal organizations globally enable millions of customers to conveniently send money worldwide. Customers may choose for their funds to be paid out into billions of bank accounts and millions of mobile wallets in approximately 120 countries, or more than half a million Agent locations in more than 200 countries and territories. This integration of Western Union’s capabilities including global settlement capabilities, financial network, compliance, and technology systems has provided access to millions of postal network customers to send cross-border money transfers quickly, conveniently and reliably.
Over decades, Western Union has built strategic collaborations with postal entities in 79 countries. These relationships have enabled us to work together and develop innovative ways to digitize the experience for joint customers.
“We are focused on continually enhancing our platform and expanding our reach to better connect people, business and communities around the world. Our growing partnerships with national postal networks are part of this commitment, and we are pleased to link our leading digital cross-border capabilities to bring real worldwide connectivity with a few taps to the global customers of our postal network partners,” said Jean Claude Farah , President, Western Union Global Network. “With expansion of our relationship with Australia Post we are continuing our recent momentum powering retail players to succeed in the digital space and unlock new growth opportunities so that together, we can serve as an economic force for our global customers.”
Farah added: “Western Union has a distinct vantage point on the diverse money movement needs of our global customers across different continents and economic, financial and technological ecosystems. Our global platform transcends these complexities, making it possible to send funds easily and quickly across borders and currencies with a few clicks.”
Western Union’s strategy to open its platform and worldwide financial network to serve third-party companies has established it as a unique partner for global money movement, enabling organizations in telecom, tech, financial services, and other sectors to enrich services for their customers.
About Western Union
The Western Union Company (NYSE: WU) is a global leader in cross-border, cross-currency money movement and payments. Western Union’s platform provides seamless cross-border flows, and its leading global financial network bridges more than 200 countries and territories and over 130 currencies. We connect businesses, financial institutions, governments, and consumers through one of the world’s widest reaching networks, accessing billions of bank accounts, millions of digital wallets and cards, and over half a million-retail locations. Western Union connects the world to bring boundless possibilities within reach. For more information, visit www.westernunion.com .
WU-G
View source version on businesswire.com: https://www.businesswire.com/news/home/20210610005042/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom